UnitedHealthcare said the quality and cost of Medtronic’s devices factored into its decision, which concerns pumps for children age 7 and older. However, some patient advocates have called the new policy — which effectively limits in-network options for the insulin pump from three to two — “an unacceptable step backward,” diabetes nonprofit JDRF told the Star Tribune.
UnitedHealthcare spokesperson Stephen Shivinsky told the publication via email that “safety and helping individuals with diabetes avoid dangerous highs and lows in their sugar levels were the key factors in our decision.”
For the full report, click here.
More articles on payers:
Payer-provider partnerships and market trends
9 ‘Best in KLAS’ value-based care consultants
Companies like LexisNexis are selling patient ‘risk scores’ to hospitals, insurers
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
